Literature DB >> 17126587

Neural agrin: a synaptic stabiliser.

Shyuan T Ngo1, Peter G Noakes, William D Phillips.   

Abstract

Neural agrin is a heparan sulphate proteoglycan first defined by its ability to induce the clustering of acetylcholine receptors (AChRs) on cultured muscle cells. Neural agrin activates the transmembrane Muscle Specific Kinase (MuSK) on the postsynaptic muscle cell to stabilise the developing neuromuscular synapse. Three biological mechanisms for agrin/MuSK signalling are briefly discussed: selective transcription of synaptic genes such as MuSK itself, to reinforce developing postsynaptic clusters of AChRs; initiation of second messenger signalling pathways that can induce the formation of AChR clusters and retrograde signalling downstream of agrin/MuSK that may transform the growth cone of the motor axon into a stable differentiated nerve terminal, specialised for regulated exocytosis of neurotransmitter. Here we briefly review some key mechanisms through which neural agrin acts to foster the formation of mature neuromuscular synapses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17126587     DOI: 10.1016/j.biocel.2006.10.012

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  14 in total

Review 1.  Casting a net on dendritic spines: the extracellular matrix and its receptors.

Authors:  Lorraine E Dansie; Iryna M Ethell
Journal:  Dev Neurobiol       Date:  2011-11       Impact factor: 3.964

2.  [Sepsis impairs aggregation of nicotinic acetylcholine receptors on murine skeletal muscle cell membranes by inhibiting AKT/GSK3β phosphorylation].

Authors:  Tianmei Li; Li Liu; Xiaobin Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-11-30

Review 3.  Extracellular matrix and heart development.

Authors:  Marie Lockhart; Elaine Wirrig; Aimee Phelps; Andy Wessels
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-05-25

4.  LG2 agrin mutation causing severe congenital myasthenic syndrome mimics functional characteristics of non-neural (z-) agrin.

Authors:  Ricardo A Maselli; Jose M Fernandez; Juan Arredondo; Carmen Navarro; Maian Ngo; David Beeson; Orla Cagney; D Colette Williams; Robert L Wollmann; Vladimir Yarov-Yarovoy; Michael J Ferns
Journal:  Hum Genet       Date:  2011-12-29       Impact factor: 4.132

5.  Proteomics characterization of extracellular space components in the human aorta.

Authors:  Athanasios Didangelos; Xiaoke Yin; Kaushik Mandal; Mark Baumert; Marjan Jahangiri; Manuel Mayr
Journal:  Mol Cell Proteomics       Date:  2010-06-15       Impact factor: 5.911

6.  Agrin regulation of alpha3 sodium-potassium ATPase activity modulates cardiac myocyte contraction.

Authors:  Lutz G W Hilgenberg; Bryan Pham; Maria Ortega; Saif Walid; Thomas Kemmerly; Diane K O'Dowd; Martin A Smith
Journal:  J Biol Chem       Date:  2009-04-16       Impact factor: 5.157

7.  Induction of Anti-agrin Antibodies Causes Myasthenia Gravis in Mice.

Authors:  Min Yan; Ziyang Liu; Erkang Fei; Wenbing Chen; Xinsheng Lai; Bin Luo; Peng Chen; Hongyang Jing; Jin-Xiu Pan; Michael H Rivner; Wen-Cheng Xiong; Lin Mei
Journal:  Neuroscience       Date:  2018-01-13       Impact factor: 3.590

Review 8.  Structural mechanisms of the agrin-LRP4-MuSK signaling pathway in neuromuscular junction differentiation.

Authors:  Yinong Zong; Rongsheng Jin
Journal:  Cell Mol Life Sci       Date:  2012-11-22       Impact factor: 9.261

9.  The formation of complex acetylcholine receptor clusters requires MuSK kinase activity and structural information from the MuSK extracellular domain.

Authors:  Sania Mazhar; Ruth Herbst
Journal:  Mol Cell Neurosci       Date:  2011-12-23       Impact factor: 4.314

10.  Tyrosine phosphatases such as SHP-2 act in a balance with Src-family kinases in stabilization of postsynaptic clusters of acetylcholine receptors.

Authors:  Alain A Camilleri; Raffaella Willmann; Gayathri Sadasivam; Shuo Lin; Markus A Rüegg; Matthias Gesemann; Christian Fuhrer
Journal:  BMC Neurosci       Date:  2007-07-02       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.